Hiddemann W - Search Results

1

Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.

Köhne CH, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Kaufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ. Köhne CH, et al. Among authors: hiddemann w. Oncology. 1997 Mar-Apr;54(2):96-101. doi: 10.1159/000227670. Oncology. 1997. PMID: 9075778 Clinical Trial.

2

Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.

Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W, Köhne-Wömpner CH, et al. Schöber C, et al. Among authors: hiddemann w. Cancer. 1993 Oct 1;72(7):2242-7. doi: 10.1002/1097-0142(19931001)72:7<2242::aid-cncr2820720730>3.0.co;2-e. Cancer. 1993. PMID: 8374883

3

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.

Harstrick A, Köhne CH, Hiddemann W, Preusser P, Strumberg D, Berns T, Seeber S, Wilke H, Schmoll HJ. Harstrick A, et al. Among authors: hiddemann w. Ann Oncol. 1997 Sep;8(9):917-8. doi: 10.1023/a:1008298102758. Ann Oncol. 1997. PMID: 9358946 Free article.

4

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ. Köhne CH, et al. Among authors: hiddemann w. J Clin Oncol. 1998 Feb;16(2):418-26. doi: 10.1200/JCO.1998.16.2.418. J Clin Oncol. 1998. PMID: 9469324 Clinical Trial.

5

Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.

Schmoll HJ, Köhne-Wömpner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schöffski P, Bokemeyer C, Lohrmann HP, Preiss J, et al. Schmoll HJ, et al. Among authors: hiddemann w. Semin Oncol. 1992 Apr;19(2 Suppl 3):191-6. Semin Oncol. 1992. PMID: 1557646 Clinical Trial.

6

Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.

Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohrmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, et al. Köhne CH, et al. Among authors: hiddemann w. J Clin Oncol. 1995 May;13(5):1201-8. doi: 10.1200/JCO.1995.13.5.1201. J Clin Oncol. 1995. PMID: 7738622 Clinical Trial.

7

Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.

Hiddemann W, Urbanitz D, Preusser P, Achterrath W, Büchner T. Hiddemann W, et al. Hematol Oncol. 1989 Jul-Aug;7(4):267-73. doi: 10.1002/hon.2900070403. Hematol Oncol. 1989. PMID: 2737607

8

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.

Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ. Köhne CH, et al. Among authors: hiddemann w. Eur J Cancer. 1997 Oct;33(11):1896-9. doi: 10.1016/s0959-8049(97)00256-6. Eur J Cancer. 1997. PMID: 9470854 Clinical Trial.

9

Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.

Verbeek W, Wörmann B, Koch P, Aul C, Hinrichs HF, Balleisen L, Rowe JM, Bennett J, Haase D, Fonatsch C, Heinecke A, Büchner T, Hiddemann W. Verbeek W, et al. Among authors: hiddemann w. J Cancer Res Clin Oncol. 1999;125(6):369-74. doi: 10.1007/s004320050288. J Cancer Res Clin Oncol. 1999. PMID: 10363570 Clinical Trial.

10

The emerging role for biomodulation of antineoplastic agents.

Schmoll HJ, Hiddemann W, Rustum Y, Köhne-Wömpner CH. Schmoll HJ, et al. Among authors: hiddemann w. Semin Oncol. 1992 Apr;19(2 Suppl 3):1-3. Semin Oncol. 1992. PMID: 1557636 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

916 results

Search Page

Filters